Market

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
Read More

Related Posts

Enanta Pharma CBO Luu sells $19,836 in stock

Enanta Pharma CBO Luu sells $19,836 in stock

Carvana gets a spot in the S&P 500 ahead of these tech stocks

Carvana gets a spot in the S&P 500 ahead of these tech ...

Spirit Airlines scraps plan to furlough up to 365 pilots

Spirit Airlines scraps plan to furlough up to 365 pilots

Adaptive Biotechnologies CSO Robins sells $672,515 in ADPT stock

Adaptive Biotechnologies CSO Robins sells $672,515 in A...

Enanta Pharma CSO Or Yat Sun sells $34k in stock

Enanta Pharma CSO Or Yat Sun sells $34k in stock

Enanta Pharma chief medical officer sells $11k in stock

Enanta Pharma chief medical officer sells $11k in stock